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LETTER TO THE EDITOR
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Levosulpiride-induced Hyper-
prolactinemia
Sir,
Dyspepsia is a common concern of patients in both the hospital
and  outpatient  settings.  For  symptomatic  treatment  of  this,
there are many over-the-counter drugs available in our country.
Levosulpiride  is  commonly  used  for  dyspepsia,  since  this
became available as a new prokinetic agent in Pakistan without a
prescription.
Previously,  prokinetic  agents  like  domperidone  and  metoclo-
pramide have been reported to cause hyperprolactinemia as one
of  their  unavoidable  side  effects  by  blocking  central  D2
dopamine receptors at the hypothalamus and anterior pituitary
level.1 However, this side effect of these old drugs in causing
hyperprolactinema was moderate, usually in the range of <100
ng/mL.  Recently,  a  few cases  have been reported with  levo-
sulpiride, causing increased serum prolactin in the range of >200
ng/mL.2
Here, we present two patients who were diagnosed with levo-
sulpiride-induced hyperprolactinemia with their prolactin level
normaliSing with discontinuation of this drug. The first patient
was a 40- year woman referred to Endocrinology Unit for the eval-
uation of galactorrhoea. Her serum prolactin was reported as
49.40 ng/mL (normal range: 4-18.5 ng/mL). The second patient
was a 28-year woman who presented with a history of irregular
periods  for  a  few  months,  serum  prolactin  checked  by  her
primary physician was 109.5 ng/mL, who then referred her to
Endocrinology Unit for further workup and management.
On detailed history taking, both admitted that they had been
experiencing  acid  peptic  symptoms  and  were  taking  Levo-
sulpiride tablets of 25 mg and 50 mg, two to three times per day,
respectively for the last 3-4 months prior to their presentation.
They were advised to stop this agent and follow-up in the clinic
after 1 month with repeat serum prolactin level. After one month,
both reported improvement in their initial symptoms and repeat
prolactin levels were 24 ng/mL and 40.40 ng/mL, respectively.
Levosulpiride acts via antagonising central D2 dopamine recep-
tors and show its therapeutics as well as adverse effects like
hyperprolactinemia by that mechanism.
Data  regarding  levosulpiride-induced  hyperprolactinemia  is
scarce. Lozano et al. in his prospective  study of 342 participants
has reported galactorrhoea in 26.7% patients on levosulpiride.3
Our intent in sending this communication is to help create aware-
ness  amongst  health  professionals  regarding  the  association
between levosulpiride and raised serum prolactin levels. In the
management process, the first step should be to discontinue levo-
sulpiride, repeat prolactin level in a few weeks; and if prolactin
levels normalise, then avoid unnecessary costly workup.
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